首页 > 最新文献

Oncology Research and Treatment最新文献

英文 中文
Guidelines: onkopedia - what´s new? Locally advanced rectal cancer. 指南:百科全书 - 新内容?局部晚期直肠癌。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-17 DOI: 10.1159/000541376
Ralf-Dieter Hofheinz,Dirk Arnold,Markus Borner,Wolfgang Eisterer,Gunnar Folprecht,Michael Ghadimi,Ullrich Graeven,Birgit Grünberger,Holger Hebart,Susanna Hegewisch-Becker,Volker Heinemann,Ron Pritzkuleit,Claus Rödel,Holger Rumpold,Tanja Trarbach,,Bernhard Wörmann
This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian and Swiss onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy (TNT) for rectal cancers with high risk features, (ii) treatment with neoadjuvant chemotherapy for patient with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high /dMMR rectal cancer as well as (iv) intended organ preservation as a treatment goal. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options and risks of individual treatment approaches.
本文简要总结了最近出版的德国、奥地利和瑞士关于局部晚期直肠癌治疗指南中与临床相关的新内容。主要内容包括:(i) 对具有高风险特征的直肠癌采用全新药辅助治疗 (TNT);(ii) 对局部复发风险较低的患者采用新药辅助化疗;(iii) 对 MSI 高/dMMR 直肠癌患者采用多司马单抗进行免疫治疗;(iv) 将保留器官作为治疗目标。由于存在多种循证治疗方案,因此需要多学科团队进行深入讨论,并向患者提供有关治疗目标、方案和各种治疗方法风险的专门信息。
{"title":"Guidelines: onkopedia - what´s new? Locally advanced rectal cancer.","authors":"Ralf-Dieter Hofheinz,Dirk Arnold,Markus Borner,Wolfgang Eisterer,Gunnar Folprecht,Michael Ghadimi,Ullrich Graeven,Birgit Grünberger,Holger Hebart,Susanna Hegewisch-Becker,Volker Heinemann,Ron Pritzkuleit,Claus Rödel,Holger Rumpold,Tanja Trarbach,,Bernhard Wörmann","doi":"10.1159/000541376","DOIUrl":"https://doi.org/10.1159/000541376","url":null,"abstract":"This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian and Swiss onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy (TNT) for rectal cancers with high risk features, (ii) treatment with neoadjuvant chemotherapy for patient with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high /dMMR rectal cancer as well as (iv) intended organ preservation as a treatment goal. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options and risks of individual treatment approaches.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"1 1","pages":"1-9"},"PeriodicalIF":2.4,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial. 紫杉醇/Ramucirumab与紫杉醇在晚期食管鳞癌二线治疗中的对比:随机 II 期 IKF-AIO-RAMOS 试验。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-09 DOI: 10.1159/000541174
Magdalena K Scheck,Thorsten O Goetze,Thomas J Ettrich,Harald Schmalenberg,Michael Clemens,Rolf Mahlberg,Steffen Heeg,Stephan Kanzler,Gunnar Hapke,Peter Thuss-Patience,Angelika Kestler,Anne Treschl,Stefan Heidel,Moritz Schiemer,Disorn Sookthai,Sabine Junge,Claudia Pauligk,Salah-Eddin Al-Batran,Sylvie Lorenzen
INTRODUCTIONIn squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line treatment in metastatic esophagogastric adenocarcinoma. We assessed safety and efficacy of ramucirumab/paclitaxel for ESCC.METHODSThis prospective, randomized, open-label, multicenter, phase II trial evaluated paclitaxel (80 mg/m2 d1, 8, 15) plus ramucirumab (8 mg/kg d1, 15) (investigational arm A) vs. paclitaxel alone (80 mg/m2 d1, 8, 15) (standard arm B), both q4w, in advanced/metastatic ESCC refractory or intolerant to fluoropyrimidine and platinum-based drugs. Primary endpoint was overall survival (OS) rate at 6 months.RESULTSFrom 3/2019 to 4/2021, 21/186 planned patients were included (arm A 11 pts; arm B 10 pts) in 9 German centres. Due to slow accrual, the study was terminated prematurely. OS at 6 months was 72.7% for ramucirumab/paclitaxel and 50.0% for paclitaxel. The study design did not allow statistical comparison of the arms. PFS (3.8 vs. 3.5 months), OS (12.1 vs. 9.2 months), ORR (18.2% vs. 20.0%) and DCR (54.5% vs. 60.0%) were comparable in both arms. Most common treatment related adverse events (TRAEs) in arm A were leucopenia (54.5%), fatigue (27.3%) and peripheral sensory neuropathy (18.2%). 27.3% in arm A and 50.0% in arm B had TRAEs ≥ grade 3.CONCLUSIONRamucirumab/paclitaxel shows an acceptable tolerability and numerically improved OS at 6 months. Due to the small number of patients the current trial must be considered exploratory and more data are needed in this indication.REGISTRATIONClinicalTrials.gov, NCT03762564. IKF-s627 RAMOS Study.
简介:在食管鳞状细胞癌(ESCC)的二线治疗中,免疫检查点抑制剂是唯一获批的治疗方案。Ramucirumab/紫杉醇是已获批准的转移性食管胃腺癌二线治疗药物。我们评估了ramucirumab/紫杉醇治疗ESCC的安全性和有效性。方法这项前瞻性、随机、开放标签、多中心、II期试验评估了紫杉醇(80 mg/m2 d1, 8, 15)加ramucirumab(8 mg/kg d1, 15)(研究组A)与单用紫杉醇(80 mg/m2 d1, 8, 15)(研究组B)的比较。紫杉醇(80 毫克/平方米,每天 1、8、15 次)与拉穆单抗(8 毫克/公斤,每天 1、15 次)(标准研究组 B),均为每天 4 次,用于治疗对氟嘧啶类和铂类药物难治或不耐受的晚期/转移性 ESCC。结果2019年3月至2021年4月,9个德国中心共纳入21/186例计划患者(A组11例;B组10例)。由于进展缓慢,研究提前结束。6个月的OS率为:ramucirumab/紫杉醇72.7%,紫杉醇50.0%。研究设计不允许对两组患者进行统计比较。两组的PFS(3.8个月 vs. 3.5个月)、OS(12.1个月 vs. 9.2个月)、ORR(18.2% vs. 20.0%)和DCR(54.5% vs. 60.0%)相当。A组最常见的治疗相关不良事件(TRAEs)为白细胞减少(54.5%)、疲劳(27.3%)和周围感觉神经病变(18.2%)。A组和B组分别有27.3%和50.0%的患者出现≥3级的TRAE。由于患者人数较少,目前的试验必须被视为探索性试验,在这一适应症方面还需要更多数据。IKF-s627 RAMOS 研究。
{"title":"Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.","authors":"Magdalena K Scheck,Thorsten O Goetze,Thomas J Ettrich,Harald Schmalenberg,Michael Clemens,Rolf Mahlberg,Steffen Heeg,Stephan Kanzler,Gunnar Hapke,Peter Thuss-Patience,Angelika Kestler,Anne Treschl,Stefan Heidel,Moritz Schiemer,Disorn Sookthai,Sabine Junge,Claudia Pauligk,Salah-Eddin Al-Batran,Sylvie Lorenzen","doi":"10.1159/000541174","DOIUrl":"https://doi.org/10.1159/000541174","url":null,"abstract":"INTRODUCTIONIn squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line treatment in metastatic esophagogastric adenocarcinoma. We assessed safety and efficacy of ramucirumab/paclitaxel for ESCC.METHODSThis prospective, randomized, open-label, multicenter, phase II trial evaluated paclitaxel (80 mg/m2 d1, 8, 15) plus ramucirumab (8 mg/kg d1, 15) (investigational arm A) vs. paclitaxel alone (80 mg/m2 d1, 8, 15) (standard arm B), both q4w, in advanced/metastatic ESCC refractory or intolerant to fluoropyrimidine and platinum-based drugs. Primary endpoint was overall survival (OS) rate at 6 months.RESULTSFrom 3/2019 to 4/2021, 21/186 planned patients were included (arm A 11 pts; arm B 10 pts) in 9 German centres. Due to slow accrual, the study was terminated prematurely. OS at 6 months was 72.7% for ramucirumab/paclitaxel and 50.0% for paclitaxel. The study design did not allow statistical comparison of the arms. PFS (3.8 vs. 3.5 months), OS (12.1 vs. 9.2 months), ORR (18.2% vs. 20.0%) and DCR (54.5% vs. 60.0%) were comparable in both arms. Most common treatment related adverse events (TRAEs) in arm A were leucopenia (54.5%), fatigue (27.3%) and peripheral sensory neuropathy (18.2%). 27.3% in arm A and 50.0% in arm B had TRAEs ≥ grade 3.CONCLUSIONRamucirumab/paclitaxel shows an acceptable tolerability and numerically improved OS at 6 months. Due to the small number of patients the current trial must be considered exploratory and more data are needed in this indication.REGISTRATIONClinicalTrials.gov, NCT03762564. IKF-s627 RAMOS Study.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"16 1","pages":"1-20"},"PeriodicalIF":2.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142224928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. bis 14. Oktober 2024, Basel. 德国、奥地利和瑞士血液学与肿瘤内科学会年会,2024 年 10 月 11-14 日,巴塞尔。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-08 DOI: 10.1159/000540557

None.

无。
{"title":"Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. bis 14. Oktober 2024, Basel.","authors":"","doi":"10.1159/000540557","DOIUrl":"https://doi.org/10.1159/000540557","url":null,"abstract":"<p><p>None.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"47 Suppl 2 ","pages":"11-354"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023. 欧洲肿瘤内科学会 2023 年年会的胃食管肿瘤学亮点。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-13 DOI: 10.1159/000538324
Magdalena K Scheck, Ira Ekmekciu, Greta Sommerhäuser, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Henning Wege, Anke Reinacher-Schick, Ralf-Dieter Hofheinz, Thorsten Oliver Götze, Sylvie Lorenzen, Alexander Edward Nieto
{"title":"Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023.","authors":"Magdalena K Scheck, Ira Ekmekciu, Greta Sommerhäuser, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Henning Wege, Anke Reinacher-Schick, Ralf-Dieter Hofheinz, Thorsten Oliver Götze, Sylvie Lorenzen, Alexander Edward Nieto","doi":"10.1159/000538324","DOIUrl":"10.1159/000538324","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"224-228"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140120228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anaemia in Hospitalized Cancer Patients: A Retrospective Study of Two Cohorts before and after the Guideline Update. 住院癌症患者的贫血症:对指南更新前后两个队列的回顾性研究。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-05-07 DOI: 10.1159/000539143
Katell Le Dû, Anne-Lise Septans, Julien Dômont, Olivier Dupuis, Eric Emmanuel, Anne Peribois, Sophie Gaillard, Caroline Allix-Béguec

Introduction: The incidence of anaemia and its consequences are often underestimated during cancer management. We propose to evaluate the situation before and after the recommendations were updated in order to assess their impact on the day-to-day practice.

Methods: In this single-centre retrospective study, eligible patients were treated for cancer and warranted overnight hospitalization over two periods (n = 206 in 2011, n = 143 in 2018). The diagnosis of anaemia was defined by a haemoglobin level below 12 and 13 g/dL for women and men, respectively.

Results: The prevalence of anaemia was 26% in 2011 and 16% in 2018 (p < 0.001). Biological assessment had changed between the two periods, with more tests of iron metabolism and measurements of inflammatory parameters. Patients hospitalized in 2018 had more advanced cancer and more severe anaemia (8.2 g/dL [±1.07] in 2011 vs. 7.9 g/dL [±1.18] in 2018). Rate of transfusion therapy did not change, but patients with mild and moderate anaemia were transfused less in 2018 (57% in 2011 vs. 44% in 2018). Intravenous iron and erythropoiesis-stimulating agent were used more frequently in 2018 (1 and 5 and 13 and 23% in 2011 and 2018, respectively), mainly for mild anaemia and life-threatening anaemia, respectively. Overall survival was poor in both cohorts at 24 months (15.4% in 2011 and 6.5% in 2018, p = 0.048).

Conclusion: Practices have changed in the diagnosis of anaemia and prescriptions for erythropoiesis-stimulating agents and intravenous iron have increased. Efforts must continue to explore the causes of anaemia, optimize patients' quality of life, and reduce transfusions.

引言 在癌症治疗过程中,贫血的发生率及其后果往往被低估。我们建议评估建议更新前后的情况,以评估其对日常实践的影响。方法 在这项单中心回顾性研究中,符合条件的癌症患者在两个时期(2011 年为 206 人,2018 年为 143 人)接受了治疗,并需要过夜住院。贫血的诊断标准是女性和男性的血红蛋白水平分别低于 12 和 13 g/dl。结果 2011 年贫血患病率为 26%,2018 年为 16%(p<.001)。两个时期的生物评估发生了变化,铁代谢测试和炎症参数测量增多。2018年住院患者的癌症晚期程度更高,贫血也更严重(2011年为8.2 g/dl [±1.07] vs 2018年为7.9 g/dl [±1.18])。输血治疗率没有变化,但轻度和中度贫血患者的输血率在2018年有所降低(2011年为57%,2018年为44%)。2018年静脉注射铁剂和促红细胞生成剂的使用频率更高(2011年和2018年分别为1%和5%,以及13%和23%),主要分别用于轻度贫血和危及生命的贫血。两个队列的 24 个月总生存率均较低(2011 年为 15.4%,2018 年为 6.5%,P=0.048)。结论 贫血诊断方法有所改变,促红细胞生成药和静脉注射铁剂的处方也有所增加。必须继续努力探索贫血的原因,优化患者的生活质量,减少输血。
{"title":"Anaemia in Hospitalized Cancer Patients: A Retrospective Study of Two Cohorts before and after the Guideline Update.","authors":"Katell Le Dû, Anne-Lise Septans, Julien Dômont, Olivier Dupuis, Eric Emmanuel, Anne Peribois, Sophie Gaillard, Caroline Allix-Béguec","doi":"10.1159/000539143","DOIUrl":"10.1159/000539143","url":null,"abstract":"<p><strong>Introduction: </strong>The incidence of anaemia and its consequences are often underestimated during cancer management. We propose to evaluate the situation before and after the recommendations were updated in order to assess their impact on the day-to-day practice.</p><p><strong>Methods: </strong>In this single-centre retrospective study, eligible patients were treated for cancer and warranted overnight hospitalization over two periods (n = 206 in 2011, n = 143 in 2018). The diagnosis of anaemia was defined by a haemoglobin level below 12 and 13 g/dL for women and men, respectively.</p><p><strong>Results: </strong>The prevalence of anaemia was 26% in 2011 and 16% in 2018 (p &lt; 0.001). Biological assessment had changed between the two periods, with more tests of iron metabolism and measurements of inflammatory parameters. Patients hospitalized in 2018 had more advanced cancer and more severe anaemia (8.2 g/dL [±1.07] in 2011 vs. 7.9 g/dL [±1.18] in 2018). Rate of transfusion therapy did not change, but patients with mild and moderate anaemia were transfused less in 2018 (57% in 2011 vs. 44% in 2018). Intravenous iron and erythropoiesis-stimulating agent were used more frequently in 2018 (1 and 5 and 13 and 23% in 2011 and 2018, respectively), mainly for mild anaemia and life-threatening anaemia, respectively. Overall survival was poor in both cohorts at 24 months (15.4% in 2011 and 6.5% in 2018, p = 0.048).</p><p><strong>Conclusion: </strong>Practices have changed in the diagnosis of anaemia and prescriptions for erythropoiesis-stimulating agents and intravenous iron have increased. Efforts must continue to explore the causes of anaemia, optimize patients' quality of life, and reduce transfusions.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"331-339"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability of End-of-Life Care Wishes and Gender-Specific Characteristics of Outpatients with Advanced Cancer under Palliative Therapy: A Prospective Observational Study. 接受姑息治疗的晚期癌症门诊患者临终关怀意愿的稳定性和性别特征。前瞻性观察研究。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-01 DOI: 10.1159/000538112
Thomas Golombek, Nora Hegewald, Astrid Schnabel, Hansjakob Fries, Florian Lordick

Introduction: Early integration of palliative care and advance care planning (ACP) play an increasingly important role in the treatment of patients with advanced cancer. Advance directives (ADs) and patients' preferences regarding end-of-life (EoL) care are important aspects of ACP. In the outpatient setting, the prevalence of those documents and EoL care wishes is not well investigated, and changes in the longitudinal course are poorly understood.

Methods: From June 2020 to August 2022, 67 outpatients with advanced solid tumors undergoing palliative cancer therapy were interviewed on the topic of ACP in a longitudinal course. From this database, the prevalence of ADs, healthcare proxy, EoL care wishes, and the need for counseling regarding these issues were collected. In addition, EoL care wishes were examined for their stability.

Results: Fifty-one patients (76.1%) reported having ADs, and 41 patients (61.2%) reported having a healthcare proxy. Nineteen patients (37.3%) with ADs and 11 patients (68.7%) without ADs indicated a wish for counseling. Reported EoL care wishes remained stable over a period of approximately 6 months. Nevertheless, intraindividual changes occurred over time within the different EoL care preferences. The desire for resuscitation and dialysis were significantly higher in men than in women (resuscitation: 15 of 21 men [71.4%] versus 9 of 22 women [40.9%], odds ratio [OR] 3.611, 95% confidence interval [CI], 1.01-12.89, p = 0.048; dialysis: 16 of the 23 men [69.6%] versus 9 of the 25 women [36.0%], OR: 4.063, 95% CI: 1.22-13.58, p = 0.023).

Conclusion: Our results show a reasonably high percentage of ADs and healthcare proxies in our study cohort. The observed stability of EoL requests encourages the implementation of structured queries for ADs and healthcare proxy for outpatients undergoing palliative treatment. Our data suggest that gender-specific characteristics should be further investigated in this context.

简介在晚期癌症患者的治疗过程中,早期整合姑息关怀和预先护理计划(ACP)发挥着越来越重要的作用。预先医疗指示(AD)和患者对生命末期(EoL)护理的偏好是 ACP 的重要方面。在门诊环境中,这些文件和临终关怀意愿的普遍性没有得到很好的调查,纵向过程中的变化也不甚了解:方法:从 2020 年 6 月到 2022 年 8 月,对 67 名接受癌症姑息治疗的晚期实体瘤门诊患者进行了关于 ACP 主题的纵向访谈。从该数据库中收集了AD的患病率、医疗保健代理、EoL护理意愿以及就这些问题进行咨询的需求。此外,还对患者的 EoL 护理意愿的稳定性进行了研究:51名患者(76.1%)报告患有注意力缺失症,41名患者(61.2%)报告有医疗代理。19名(37.3%)有注意力缺失症的患者和 11 名(68.7%)无注意力缺失症的患者表示希望获得心理咨询。在大约 6 个月的时间里,所报告的 EoL 护理愿望保持稳定。然而,随着时间的推移,在不同的起居护理偏好中,个体内部也发生了变化。男性对复苏和透析的愿望明显高于女性(复苏:21 位男性中有 15 位(71.4%)希望进行透析;透析:21 位男性中有 15 位(71.4%)希望进行复苏):21名男性中的15人(71.4%)与22名女性中的9人(40.9%)相比,几率比[OR]为3.611,95%置信区间[CI]为1.01至12.89,P=0.048;透析:23名男性中的16人(69.6%)与25名女性中的9人(36.0%)相比,OR为4.063,95%置信区间[CI]为1.22至13.58,P=0.023):我们的研究结果表明,在我们的研究队列中,AD 和医疗保健代理的比例相当高。观察到的EoL请求的稳定性鼓励对接受姑息治疗的门诊患者进行AD和医疗代理的结构化查询。我们的数据表明,在这种情况下应进一步调查性别特征。
{"title":"Stability of End-of-Life Care Wishes and Gender-Specific Characteristics of Outpatients with Advanced Cancer under Palliative Therapy: A Prospective Observational Study.","authors":"Thomas Golombek, Nora Hegewald, Astrid Schnabel, Hansjakob Fries, Florian Lordick","doi":"10.1159/000538112","DOIUrl":"10.1159/000538112","url":null,"abstract":"<p><strong>Introduction: </strong>Early integration of palliative care and advance care planning (ACP) play an increasingly important role in the treatment of patients with advanced cancer. Advance directives (ADs) and patients' preferences regarding end-of-life (EoL) care are important aspects of ACP. In the outpatient setting, the prevalence of those documents and EoL care wishes is not well investigated, and changes in the longitudinal course are poorly understood.</p><p><strong>Methods: </strong>From June 2020 to August 2022, 67 outpatients with advanced solid tumors undergoing palliative cancer therapy were interviewed on the topic of ACP in a longitudinal course. From this database, the prevalence of ADs, healthcare proxy, EoL care wishes, and the need for counseling regarding these issues were collected. In addition, EoL care wishes were examined for their stability.</p><p><strong>Results: </strong>Fifty-one patients (76.1%) reported having ADs, and 41 patients (61.2%) reported having a healthcare proxy. Nineteen patients (37.3%) with ADs and 11 patients (68.7%) without ADs indicated a wish for counseling. Reported EoL care wishes remained stable over a period of approximately 6 months. Nevertheless, intraindividual changes occurred over time within the different EoL care preferences. The desire for resuscitation and dialysis were significantly higher in men than in women (resuscitation: 15 of 21 men [71.4%] versus 9 of 22 women [40.9%], odds ratio [OR] 3.611, 95% confidence interval [CI], 1.01-12.89, p = 0.048; dialysis: 16 of the 23 men [69.6%] versus 9 of the 25 women [36.0%], OR: 4.063, 95% CI: 1.22-13.58, p = 0.023).</p><p><strong>Conclusion: </strong>Our results show a reasonably high percentage of ADs and healthcare proxies in our study cohort. The observed stability of EoL requests encourages the implementation of structured queries for ADs and healthcare proxy for outpatients undergoing palliative treatment. Our data suggest that gender-specific characteristics should be further investigated in this context.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"189-197"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series. 四肢和躯干骨骼外尤文肉瘤:对单个机构系列病例的回顾性分析。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-07-31 DOI: 10.1159/000540613
Giuseppe Bianchi, Maria Antonella Laginestra, Elisa Simonetti, Toni Ibrahim, Fabiana Macrì, Federico Ostetto, Gianmarco Tuzzato, Anna Paioli, Marco Gambarotti, Stefania Cocchi, Davide Maria Donati, Katia Scotlandi, Roberta Laranga

Introduction: Extraskeletal Ewing sarcoma (EEwS) is a rare malignant tumor, and current international recommendations indicate systemic and local treatment like bone Ewing sarcoma (BEwS); to the best of our knowledge, very few studies tried to explore the clinical and genetic characteristics of this tumor, and the most appropriate treatment strategy remains uncertain.

Methods: We reviewed 35 EEwS cases enrolled at Rizzoli Orthopedic Institute in Bologna, Italy, between 1988-2022. We performed RNA sequencing in 18 Ewing sarcoma cases, including 12 BEwSs and 6 EEwSs. We analyzed overall survival (OS), local relapse-free survival (LRFS), and metastasis-free survival (MFS) and the risk factors associated to survival.

Results: Unsupervised hierarchical clustering showed no differences in the transcriptional profile between EEwS and BEwS. Five-year OS was 67% (95% confidence interval [CI]: 47-80), 5-year LRFS was 61% (95% CI: 43-75), and 5-year MFS was 55% (95% CI: 38-70). Recurrent tumors, larger than 8 cm, and elevated lactate dehydrogenase (LDH) serum value resulted to be negative prognostic factors.

Conclusions: The finding/detection of a genetic profile that is indistinguishable between EEwS and BEwS confirms the view that the two subgroups belong to the same tumor entity and supports the use of a single therapeutic approach for Ewing sarcoma, regardless of the site of origin. Statistical evaluation showed that size bigger than 8 cm, elevated LDH, and recurrent tumors had a worse prognosis, suggesting a risk-stratification method for identifying patients for specific therapy treatment. However, larger, multicenter, prospective trials are called for to validate our findings.

导言:骨外尤文肉瘤是一种罕见的恶性肿瘤,目前国际上的建议是像骨尤文肉瘤一样进行全身和局部治疗;据我们所知,很少有研究试图探索这种肿瘤的临床和遗传特征,最合适的治疗策略仍不确定。方法 我们回顾了意大利博洛尼亚里佐利骨科研究所 1988-2022 年间登记的 35 例骨骼外尤文肉瘤(EEwS)病例。我们对 18 例尤文肉瘤进行了 RNA 测序,其中包括 12 例骨尤文肉瘤(BEwS)和 6 例 EEwS。我们分析了总生存率(OS)、无局部复发生存率(LRFS)和无转移生存率(MFS)以及与生存率相关的风险因素。结果 无监督层次聚类显示,EEwS和BEwS的转录谱无差异。5年OS为67%(95%CI 47-80),5年LRFS为61%(95%CI 43-75),5年MFS为55%(95%CI 38-70)。肿瘤复发、大于 8 厘米和 LDH 血清值升高是预后不良的因素。结论 EEwS和BEwS的遗传特征没有区别,这证实了将这两个亚组归入同一肿瘤实体的观点,并支持对尤文肉瘤采用单一的治疗方法,而不受起源部位的影响。统计评估显示,肿瘤大小超过8厘米、LDH升高和复发的肿瘤预后较差,这表明有一种风险分级方法可用于识别接受特定治疗的患者。不过,还需要更大规模的多中心前瞻性试验来验证我们的发现。
{"title":"Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series.","authors":"Giuseppe Bianchi, Maria Antonella Laginestra, Elisa Simonetti, Toni Ibrahim, Fabiana Macrì, Federico Ostetto, Gianmarco Tuzzato, Anna Paioli, Marco Gambarotti, Stefania Cocchi, Davide Maria Donati, Katia Scotlandi, Roberta Laranga","doi":"10.1159/000540613","DOIUrl":"10.1159/000540613","url":null,"abstract":"<p><strong>Introduction: </strong>Extraskeletal Ewing sarcoma (EEwS) is a rare malignant tumor, and current international recommendations indicate systemic and local treatment like bone Ewing sarcoma (BEwS); to the best of our knowledge, very few studies tried to explore the clinical and genetic characteristics of this tumor, and the most appropriate treatment strategy remains uncertain.</p><p><strong>Methods: </strong>We reviewed 35 EEwS cases enrolled at Rizzoli Orthopedic Institute in Bologna, Italy, between 1988-2022. We performed RNA sequencing in 18 Ewing sarcoma cases, including 12 BEwSs and 6 EEwSs. We analyzed overall survival (OS), local relapse-free survival (LRFS), and metastasis-free survival (MFS) and the risk factors associated to survival.</p><p><strong>Results: </strong>Unsupervised hierarchical clustering showed no differences in the transcriptional profile between EEwS and BEwS. Five-year OS was 67% (95% confidence interval [CI]: 47-80), 5-year LRFS was 61% (95% CI: 43-75), and 5-year MFS was 55% (95% CI: 38-70). Recurrent tumors, larger than 8 cm, and elevated lactate dehydrogenase (LDH) serum value resulted to be negative prognostic factors.</p><p><strong>Conclusions: </strong>The finding/detection of a genetic profile that is indistinguishable between EEwS and BEwS confirms the view that the two subgroups belong to the same tumor entity and supports the use of a single therapeutic approach for Ewing sarcoma, regardless of the site of origin. Statistical evaluation showed that size bigger than 8 cm, elevated LDH, and recurrent tumors had a worse prognosis, suggesting a risk-stratification method for identifying patients for specific therapy treatment. However, larger, multicenter, prospective trials are called for to validate our findings.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"496-508"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141860508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers and Facilitators in Continuous Medical Education Related to Allogeneic Stem Cell Transplantation: A Qualitative Study of Physicians. 与同种异体干细胞移植相关的持续医学教育的障碍和促进因素--对医生的定性研究。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-24 DOI: 10.1159/000536429
Sascha Eickmann, Daniel Wolff, Guido Kobbe, Peter Dreger, Nicolaus Kröger, Anne Herrmann-Johns

Introduction: This study explored qualitatively, in a sample of German hematologists working in clinical allogeneic hematopoietic stem cell transplantation (alloHSCT), perceptions of barriers and facilitators to participate in continuous medical education (CME), to provide detailed information on how to improve participation in CME activities related to alloHSCT, which may also be applicable to other areas of medicine.

Methods: Based on a recruitment campaign of the German Association for Hematopoietic Stem Cell Transplantation (DAG-HSZT), 21 semi-structured telephone interviews were conducted, transcribed, and analyzed using framework analysis.

Results: Three clusters of barriers were identified that explain why alloHSCT physicians may or may not participate in CME: individual constraints (e.g., better networking, young physicians being overwhelmed by the complexity of alloHSCT), structural constraints (e.g., time and financial issues, tailoring CME courses according to the targeted audience), and content-related constraints (e.g., requirement of CME sessions, provision of an overview of CME courses, more flexible offers). We discuss the ten most frequently raised issues, including the use of incentives and the need for support at the start of residency, staff shortages, and requirements for learning sessions.

Conclusion: There is a need for a paradigm shift in CME related to alloHSCT toward a more individualized and needs-based approach. Close monitoring of residents' needs and learning progress, as well as feedback systems, could help identify appropriate CME courses that should be integrated into a tiered learning system. CME should be more targeted to specific audiences (i.e., residents, fellows, and attendees) to provide training that is tailored to individual CME needs. On-demand courses can help balance work and family obligations. Finally, peer-reviewed, up-to-date information platforms should be expanded.

研究背景 本研究以德国从事临床异基因造血干细胞移植(alloHSCT)的血液学专家为样本,定性地探讨了他们对参与继续医学教育(CME)的障碍和促进因素的看法,从而提供了如何提高参与与alloHSCT相关的继续医学教育活动的详细信息,这些信息可能也适用于其他医学领域。方法 根据德国造血干细胞移植协会(DAG-HSZT)的一次招募活动,进行了 21 次半结构式电话访谈,将访谈内容转录并使用框架分析法进行分析。结果 确定了三类障碍,解释了异体造血干细胞移植医师为何可能参加或可能不参加继续医学教育:个人制约因素(如更好的人际关系网络、年轻医师被异体造血干细胞移植的复杂性压垮)、结构性制约因素(如时间和经济问题、根据目标受众量身定制继续医学教育课程)以及与内容相关的制约因素(如对继续医学教育课程的要求、提供继续医学教育课程概览、提供更灵活的课程)。我们讨论了十个最常见的问题,包括使用激励措施和在住院医师培训开始时提供支持的必要性、人员短缺以及对学习课程的要求。结论 与异体母细胞移植相关的继续医学教育需要转变模式,采用更加个性化和以需求为基础的方法。密切关注住院医师的需求和学习进度以及反馈系统有助于确定合适的继续医学教育课程,并将其纳入阶梯式学习系统。继续医学教育应更密切地关注特定的目标人群(即住院医师、研究员和与会者),提供适合个人需要的继续医学教育培训。点播课程可能有助于在工作和家庭义务之间取得平衡。最后,应扩大经同行评审的最新信息平台。
{"title":"Barriers and Facilitators in Continuous Medical Education Related to Allogeneic Stem Cell Transplantation: A Qualitative Study of Physicians.","authors":"Sascha Eickmann, Daniel Wolff, Guido Kobbe, Peter Dreger, Nicolaus Kröger, Anne Herrmann-Johns","doi":"10.1159/000536429","DOIUrl":"10.1159/000536429","url":null,"abstract":"<p><strong>Introduction: </strong>This study explored qualitatively, in a sample of German hematologists working in clinical allogeneic hematopoietic stem cell transplantation (alloHSCT), perceptions of barriers and facilitators to participate in continuous medical education (CME), to provide detailed information on how to improve participation in CME activities related to alloHSCT, which may also be applicable to other areas of medicine.</p><p><strong>Methods: </strong>Based on a recruitment campaign of the German Association for Hematopoietic Stem Cell Transplantation (DAG-HSZT), 21 semi-structured telephone interviews were conducted, transcribed, and analyzed using framework analysis.</p><p><strong>Results: </strong>Three clusters of barriers were identified that explain why alloHSCT physicians may or may not participate in CME: individual constraints (e.g., better networking, young physicians being overwhelmed by the complexity of alloHSCT), structural constraints (e.g., time and financial issues, tailoring CME courses according to the targeted audience), and content-related constraints (e.g., requirement of CME sessions, provision of an overview of CME courses, more flexible offers). We discuss the ten most frequently raised issues, including the use of incentives and the need for support at the start of residency, staff shortages, and requirements for learning sessions.</p><p><strong>Conclusion: </strong>There is a need for a paradigm shift in CME related to alloHSCT toward a more individualized and needs-based approach. Close monitoring of residents' needs and learning progress, as well as feedback systems, could help identify appropriate CME courses that should be integrated into a tiered learning system. CME should be more targeted to specific audiences (i.e., residents, fellows, and attendees) to provide training that is tailored to individual CME needs. On-demand courses can help balance work and family obligations. Finally, peer-reviewed, up-to-date information platforms should be expanded.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"136-144"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10997258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laser Interstitial Thermal Therapy in a Large Thalamic Glioma with Long-Term Remission: A Case Report. 激光间质热疗治疗大丘脑胶质瘤并获得长期缓解:病例报告。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-26 DOI: 10.1159/000535991
Alexander Hoyningen, Kira-Lee Koster, Marian C Neidert, Oliver Bozinov, Arno Lauber, Olaf Chan-Hi Kim, Thomas Hundsberger, Marie T Krüger

Introduction: Thalamic gliomas pose a particular therapeutic challenge as complete resection is rarely achieved due to the deep and eloquent location. Laser interstitial thermal therapy (LITT) may provide a valuable management option for deep-seated gliomas that are not accessible with open surgery.

Case presentation: A 57-year-old woman presented with a rapidly progressive large thalamic glioblastoma. Opting for full ablation, we selected a challenging trajectory to maximize the possibility of full ablation. At 2.4 cm in diameter, the tumour was larger than recommended for LITT; nevertheless, three laser ablations along a single trajectory resulted in macroscopic ablation without complications. Adjuvant radio-chemotherapy was started soon after surgery without radiological recurrence 1.5 years after the initial surgery.

Conclusion: This case demonstrates the potential when thalamic tumours are managed with timely LITT treatment and meticulous trajectory planning. Moreover, it highlights the need for close interdisciplinary management with neurosurgeons, neuropathologists, neuroradiologists, and neurooncologists.

简介丘脑胶质瘤是一种特殊的治疗难题,因为其位置深且视野清晰,很少能实现完全切除。激光间质热疗(LITT)可为开放性手术无法切除的深部胶质瘤提供有价值的治疗方案:病例介绍:一名 57 岁的女性患有进展迅速的丘脑大胶质母细胞瘤。为了最大限度地实现完全消融,我们选择了一个具有挑战性的手术路径。肿瘤直径为 2.4 厘米,比建议的 LITT 更大;尽管如此,沿单一轨迹进行的三次激光消融术均实现了大面积消融,且未出现并发症。术后很快就开始了辅助放射化疗,在首次手术 1.5 年后未出现放射性复发:本病例展示了丘脑肿瘤通过及时的 LITT 治疗和精心的轨迹规划所具有的潜力。此外,该病例还强调了与神经外科医生、神经病理学家、神经放射学家和神经肿瘤学家进行密切的跨学科管理的必要性。
{"title":"Laser Interstitial Thermal Therapy in a Large Thalamic Glioma with Long-Term Remission: A Case Report.","authors":"Alexander Hoyningen, Kira-Lee Koster, Marian C Neidert, Oliver Bozinov, Arno Lauber, Olaf Chan-Hi Kim, Thomas Hundsberger, Marie T Krüger","doi":"10.1159/000535991","DOIUrl":"10.1159/000535991","url":null,"abstract":"<p><strong>Introduction: </strong>Thalamic gliomas pose a particular therapeutic challenge as complete resection is rarely achieved due to the deep and eloquent location. Laser interstitial thermal therapy (LITT) may provide a valuable management option for deep-seated gliomas that are not accessible with open surgery.</p><p><strong>Case presentation: </strong>A 57-year-old woman presented with a rapidly progressive large thalamic glioblastoma. Opting for full ablation, we selected a challenging trajectory to maximize the possibility of full ablation. At 2.4 cm in diameter, the tumour was larger than recommended for LITT; nevertheless, three laser ablations along a single trajectory resulted in macroscopic ablation without complications. Adjuvant radio-chemotherapy was started soon after surgery without radiological recurrence 1.5 years after the initial surgery.</p><p><strong>Conclusion: </strong>This case demonstrates the potential when thalamic tumours are managed with timely LITT treatment and meticulous trajectory planning. Moreover, it highlights the need for close interdisciplinary management with neurosurgeons, neuropathologists, neuroradiologists, and neurooncologists.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"42-48"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of Dietary Factors with Cutaneous Melanoma: A Case-Control Study in Greece with Literature Review. 饮食因素与皮肤黑色素瘤的关系:希腊病例对照研究及文献综述。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-12 DOI: 10.1159/000538278
Andreas Katsimpris, Antonios G Antoniadis, Nick Dessypris, Konstantinos Karampinos, Helen J Gogas, Eleni T Petridou

Introduction: It has been postulated that nutrition may influence the risk for cutaneous melanoma (CM); therefore, we aimed to assess the associations of food groups and individual nutrient intakes with CM in a Greek population.

Methods: In this case-control study, 151 patients with histologically confirmed CM, newly diagnosed and treated in the Oncology Department of the "Laikon" University Hospital (Athens, Greece), and 151 age- and sex-matched healthy individuals residing in the Athens metropolitan area, recruited among participants for routine health examinations, were included. All participants completed a questionnaire comprising anthropometric measurements, sociodemographic, lifestyle, and health-related variables. A validated, semiquantitative food frequency questionnaire was used to assess average consumption of 136 food items during the 12 months preceding the onset of disease. Multivariate conditional regression models were used to derive odds ratios (ORs) with 95% confidence intervals (95% CI) regarding the association of nine food groups and seven macronutrients with CM.

Results: Statistically significant positive associations with CM were found with higher energy intake (OR: 1.67, 95% CI: 1.22-2.30) and intake of saturated fatty acids (OR: 2.28, 95% CI: 1.00-5.28), after adjusting for sun sensitivity, major depression history, and alcohol intake. Inverse associations with higher intake of milk and dairy products (OR: 0.65, 95% CI: 0.48-0.88), fruits (OR: 0.68, 95% CI: 0.51-0.90), added lipids (OR: 0.65, 95% CI: 0.47-0.91), and sugars and syrups (OR: 0.70, 95% CI: 0.53-0.93) were also observed.

Conclusions: Beyond intrinsic risk factors, our results support associations of CM with multiple food groups and nutrients; if confirmed by prospective studies, these findings can add further knowledge about this fatal cancer.

简介:营养可能会影响皮肤黑色素瘤(CM)的发病风险:据推测,营养可能会影响皮肤黑色素瘤(CM)的发病风险;因此,我们旨在评估希腊人群中食物种类和单项营养素摄入量与CM的相关性:在这项病例对照研究中,我们纳入了 151 名组织学确诊的皮肤黑色素瘤患者,他们都是在希腊雅典 "Laikon "大学医院肿瘤科接受治疗的新确诊患者;同时还纳入了 151 名年龄和性别相匹配的健康人,他们都居住在雅典大都会地区,是在常规健康检查参与者中招募的。所有参与者都填写了一份问卷,内容包括人体测量、社会人口学、生活方式和健康相关变量。他们还使用了一份经过验证的半定量食物频率问卷,以评估发病前 12 个月内 136 种食物的平均消耗量。采用多变量条件回归模型得出了九类食物和七种宏量营养素与中医的几率比(ORs)及 95% 置信区间(95% CI):在对阳光敏感性、重度抑郁症病史和酒精摄入量进行调整后,发现能量摄入量越高(OR:1.67,95% CI:1.22-2.30),饱和脂肪酸摄入量越高(OR:2.28,95% CI:1.00-5.28),与中风呈统计学意义上的正相关。此外,还观察到与牛奶和乳制品(OR:0.65,95% CI:0.48-0.88)、水果(OR:0.68,95% CI:0.51-0.90)、添加脂质(OR:0.65,95% CI:0.47-0.91)以及糖和糖浆(OR:0.70,95% CI:0.53-0.93)摄入量较高呈反向关系:除了内在的风险因素外,我们的研究结果还支持中医与多种食物组和营养素的关联;如果得到前瞻性研究的证实,这些发现将为这一致命癌症增添更多的知识。
{"title":"Associations of Dietary Factors with Cutaneous Melanoma: A Case-Control Study in Greece with Literature Review.","authors":"Andreas Katsimpris, Antonios G Antoniadis, Nick Dessypris, Konstantinos Karampinos, Helen J Gogas, Eleni T Petridou","doi":"10.1159/000538278","DOIUrl":"10.1159/000538278","url":null,"abstract":"<p><strong>Introduction: </strong>It has been postulated that nutrition may influence the risk for cutaneous melanoma (CM); therefore, we aimed to assess the associations of food groups and individual nutrient intakes with CM in a Greek population.</p><p><strong>Methods: </strong>In this case-control study, 151 patients with histologically confirmed CM, newly diagnosed and treated in the Oncology Department of the \"Laikon\" University Hospital (Athens, Greece), and 151 age- and sex-matched healthy individuals residing in the Athens metropolitan area, recruited among participants for routine health examinations, were included. All participants completed a questionnaire comprising anthropometric measurements, sociodemographic, lifestyle, and health-related variables. A validated, semiquantitative food frequency questionnaire was used to assess average consumption of 136 food items during the 12 months preceding the onset of disease. Multivariate conditional regression models were used to derive odds ratios (ORs) with 95% confidence intervals (95% CI) regarding the association of nine food groups and seven macronutrients with CM.</p><p><strong>Results: </strong>Statistically significant positive associations with CM were found with higher energy intake (OR: 1.67, 95% CI: 1.22-2.30) and intake of saturated fatty acids (OR: 2.28, 95% CI: 1.00-5.28), after adjusting for sun sensitivity, major depression history, and alcohol intake. Inverse associations with higher intake of milk and dairy products (OR: 0.65, 95% CI: 0.48-0.88), fruits (OR: 0.68, 95% CI: 0.51-0.90), added lipids (OR: 0.65, 95% CI: 0.47-0.91), and sugars and syrups (OR: 0.70, 95% CI: 0.53-0.93) were also observed.</p><p><strong>Conclusions: </strong>Beyond intrinsic risk factors, our results support associations of CM with multiple food groups and nutrients; if confirmed by prospective studies, these findings can add further knowledge about this fatal cancer.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"206-217"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncology Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1